Clinical outcomes of vitamin D deficiency and supplementation in cancer patients

Date of this Version


Document Type

Journal Article

Publication Details

Citation only

Teleni, L., Baker, J., Koczwara, B., Kimlin, M. G., Walpole, E., Tsai, K., & Isenring, E. A. (2013). Clinical outcomes of vitamin D deficiency and supplementation in cancer patients. Nutrition Reviews, 71(9), 611-621.

Access the journal

© Copyright,Wiley , 2013

2013 HERDC Submission FoR code: 111199




Results of recent studies suggest that circulating levels of vitamin D may play an important role in cancer-specific outcomes. The present systematic review was undertaken to determine the prevalence of vitamin D deficiency (<25nmol/L) and insufficiency (25-50nmol/L) in cancer patients and to evaluate the association between circulating calcidiol (the indicator of vitamin D status) and clinical outcomes. A systematic search of original, peer-reviewed studies on calcidiol at cancer diagnosis, and throughout treatment and survival, was conducted yielding 4,706 studies. A total of 37 studies met the inclusion criteria for this review. Reported mean blood calcidiol levels ranged from 24.7 to 87.4nmol/L, with up to 31% of patients identified as deficient and 67% as insufficient. The efficacy of cholecalciferol supplementation for raising the concentration of circulating calcidiol is unclear; standard supplement regimens of <1,000IU D3/day may not be sufficient to maintain adequate concentrations or prevent decreasing calcidiol. Dose-response studies linking vitamin D status to musculoskeletal and survival outcomes in cancer patients are lacking.

This document is currently not available here.



This document has been peer reviewed.